Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News Editorials & Other Articles General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search

NNadir

(37,453 posts)
Thu Jan 29, 2026, 07:54 AM 9 hrs ago

Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

During the Covid crisis, the Moderna vaccine saved countless lives, but the orange pedophile in the White House and his unqualified brain worm bear killing boy don't believe in a "right to life" for post-fetal beings:

Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials.

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

“We do not foresee investing in new phase 3 studies in a foreseeable futures [sic] in vaccines,” Moderna’s CEO Stéphane Bancel told Bloomberg TV, placing emphasis on the word “new.”

When asked if the anti-vaccine climate is going to affect Moderna’s business and ability to develop more vaccines, Bancel said, “100%.”

You cannot make a return on investment if you don't have access to the U.S. market, or because of delays—regulatory-wise—or because your market is much smaller, because you don't have a recommendation by the government,” Bancel said yesterday on the ‍sidelines of the World Economic Forum in Davos, Switzerland.


Currently, the company touts 12 viral or bacterial vaccine programs in phase 2 development or earlier, according to its online pipeline.

When reached for comment, a Moderna spokesperson pointed to the company’s priorities set out in its Nov. 20 earnings release. At the time, the mRNA specialist announced the discontinuation of four clinical mRNA programs and outlined a three-year business strategy with the goal of boosting revenue by 10% in 2026.

“Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” Bancel said at the time...
3 replies = new reply since forum marked as read
Highlight: NoneDon't highlight anything 5 newestHighlight 5 most recent replies
Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials (Original Post) NNadir 9 hrs ago OP
F*#! cachukis 9 hrs ago #1
The insurance companies should take over funding Sweet Rosie Red 8 hrs ago #2
Malaria is not rare. Neither is HIV. Why not develop an anti malaria applegrove 3 hrs ago #3

Sweet Rosie Red

(32 posts)
2. The insurance companies should take over funding
Thu Jan 29, 2026, 09:29 AM
8 hrs ago

given the cost of treating such expensive patients! Of course, just over the horizon, peeks through ugliest fantasies of the oligargarchs; Lifetime limits, preexisting conditions, and death, death, death!

applegrove

(130,821 posts)
3. Malaria is not rare. Neither is HIV. Why not develop an anti malaria
Thu Jan 29, 2026, 01:40 PM
3 hrs ago

or anti HIV vaccine? Hmmmmmmm?

Latest Discussions»Culture Forums»Science»Anti-vaccine sentiment pu...